The decades-long timelines and low success rates of pharmaceutical drug discovery and development required a fundamental rethinking of biotechnology R&D infrastructure and its economic models. The current paradigm, characterized by declining R&D efficiency and volatile funding cycles, stifles innovation and hinders the translation of scientific breakthroughs into tangible health benefits, particularly those that extend human and animal peakspan and healthspan, which could unlock trillions in economic and societal value. In this chapter, we expand on the concept of the Integrated Longevity Biotechnology Ecosystem, or “Longevity Real Estate,” a purpose-built research and clinical ecosystem uniting residential, commercial, clinical, and research facilities run by individual AI systems controlled by a central, AI-driven operating system. We also explore how this fully-integrated longitudinal approach to longevity biotechnology can reform the cost structures of both real estate and drug discovery. The longevity biotechnology ecosystem functions as a multi-sided platform integrating health data collection, smart living environments, and federated learning for secure, privacy-preserving biomedical research. We also introduce a novel economic model designed to sustain this ecosystem through diversified, acyclical revenue streams derived from integrated services, data monetization, and strategic partnerships. This model ensures sustainable funding for innovation independent of traditional venture capital cycles. By integrating real estate, biotechnology, research hospitals, and community services, this paradigm maximizes data utility, accelerates drug discovery, and offers a viable pathway toward improving healthspan and reshaping the economics of global drug development.